Aida Ramos
Adult Health · Linden, NJNPI 1255574307
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 506 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 506 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Amgen$952
- Boehringer Ingelheim$879
- AstraZeneca$749
- Lilly USA, LLC$732
- AbbVie$686
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,029100%
- Education$200%
- Gifts$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 54 | $1,454 |
| Amgen(2 entities) | 40 | $952 |
| Boehringer Ingelheim | 57 | $879 |
| AstraZeneca | 28 | $749 |
| Lilly USA, LLC | 60 | $732 |
| AbbVie | 54 | $686 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 44 | $652 |
| Novartis | 30 | $487 |
| Novo Nordisk | 29 | $428 |
| Bayer | 20 | $385 |
| Sanofi-aventis U.S. LLC | 6 | $271 |
| Pfizer | 21 | $259 |
| Amarin Pharma, Inc. | 15 | $212 |
| Gilead | 5 | $123 |
| Merck | 8 | $115 |
| Madrigal Pharmaceuticals | 1 | $108 |
| Ardelyx, Inc. | 5 | $102 |
| Hologic Sales And Service, LLC | 2 | $52 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Scilex Pharmaceuticals Inc. | 3 | $41 |
| Exact Sciences | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Dexcom, Inc. | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Abbott | 1 | $23 |
| Ascend Therapeutics US, LLC | 1 | $18 |
| Averitas Pharma Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| BD | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$500
- Repatha$360
- BREZTRI$249
- SOLIQUA 100/33$125
- Otezla$125
- AREXVY$125
- JARDIANCE$124
- REZDIFFRA$108
- Epclusa$100
How this compares
$9,067 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 536 | $440,013 |
| TrulicityDulaglutide | 224 | $257,343 |
| OzempicSemaglutide | 212 | $228,473 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 293 | $201,525 |
| TradjentaLinagliptin | 244 | $179,210 |
| KerendiaFinerenone | 184 | $156,813 |
| MounjaroTirzepatide | 143 | $154,538 |
| FarxigaDapagliflozin Propanediol | 150 | $153,140 |
| Repatha SureclickEvolocumab | 169 | $117,829 |
| JanuviaSitagliptin Phosphate | 107 | $93,150 |
| JanumetSitagliptin Phos/Metformin Hcl | 91 | $83,994 |
| ProliaDenosumab | 45 | $77,784 |
| EliquisApixaban | 111 | $77,647 |
| LinzessLinaclotide | 112 | $72,071 |
| VascepaIcosapent Ethyl | 160 | $62,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Synjardy Xr, Jentadueto | $879 | $810,6481,014 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $732 | $411,881367 claims |
| Novo NordiskOzempic, Rybelsus | $428 | $267,184249 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,454 | $225,978354 claims |
| MerckJanuvia, Janumet, Janumet Xr | $115 | $205,098227 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $749 | $196,261285 claims |
| BayerKerendia | $385 | $156,813184 claims |
| AbbVieLinzess, Restasis | $686 | $84,413126 claims |
| AmgenProlia | $952 | $77,78445 claims |
| PfizerEliquis | $259 | $77,647111 claims |
| NovartisEntresto | $487 | $23,61230 claims |
| Johnson & JohnsonXarelto | $17 | $17,73312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.
Other adult health in Linden
- June HalperHackensack$358K
- Kara SaggiomoCamden$127K
- Entela AhmetiPomona$75K
- Phyllis McKiernanHackensack$72K
- Denise ForceMiddletown$71K
- Kathleen SenecaHillsborough$64K
- Diane AndresenNorthvale$60K
- Dana BeenstockFreehold$51K
- Phyllis DudaCamden$46K
- Anthony WalkoWestwood$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.